ERT Named Preferred Provider for IVR Administration of Key Quality of Life Assessments
ERT has been named a preferred provider for the administration of the EuroQol Group's EQ-5D patient reported outcome assessment.
ERT, a global solutions provider for patient safety and efficacy endpoint data collection, has been named a preferred provider for the administration of the EuroQol Group’s EQ-5D patient reported outcome (PRO) assessment. Specifically, VIAPhone, ERT’s Interactive Voice Response (IVR) system, has been approved to capture both the EQ-5D-3L and the EQ-5D-5L versions of the quality of life assessment.
The EuroQol Group comprises a network of international, multilingual, multidisciplinary researchers, originally from seven centers in England, Finland, the Netherlands, Norway and Sweden. It is the copyright owner of the scales, which utilizes a three or five level severity scale in the following five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
